TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that it has earned a $2 million milestone payment from Meda AB, (OMX Nordic Exchange: MEDA-A-ST), for the first commercial shipment of Ceplene® (histamine dihydrochloride) to a major country in the European Union, as defined in the agreement. The milestone payment is part of an exclusive commercial licensing agreement for Ceplene® with Meda in Europe and certain Pacific Rim countries signed by the two companies in January, 2010.
